Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a hold rating in a research note published on Sunday.

ALNY has been the topic of several other research reports. JPMorgan Chase & Co. cut their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. HC Wainwright lowered their price objective on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday. Oppenheimer cut their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Finally, Royal Bank Of Canada cut their target price on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $396.72.

Alnylam Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ ALNY opened at $218.98 on Friday. Alnylam Pharmaceuticals has a twelve month low of $197.81 and a twelve month high of $495.55. The firm has a market cap of $29.30 billion, a PE ratio of 40.70 and a beta of 0.30. The business has a fifty day simple moving average of $284.89 and a two-hundred day simple moving average of $308.81. The company has a quick ratio of 3.06, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. MV Capital Management Inc. purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at about $29,000. HM Payson & Co. purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $27,000. Golden State Wealth Management LLC boosted its holdings in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Raymond James upgraded Alnylam to “strong buy” and set a $420 price target, signaling confidence in the company’s long-term outlook. Raymond James upgrade report
• Positive Sentiment: Truist Financial maintained a “buy” rating while lowering its price target to $315 from $410. Citigroup also retained a “buy” rating with a $340 target, and Barclays kept an “overweight” rating with a $450 target. These targets remain materially above the current trading level, suggesting analysts continue to see recovery potential. Analyst price-target updates
• Neutral Sentiment: Chardan Capital reiterated its “buy” rating. Wells Fargo, Stifel Nicolaus and Royal Bank of Canada also reduced their targets to $316, $318 and $350, respectively, reflecting more cautious valuation assumptions despite generally constructive views on the shares. Chardan rating report Wells Fargo price-target report
• Negative Sentiment: Several law firms announced or continued investigations into possible securities-law violations involving Alnylam. The firms are soliciting investors who suffered losses, but these announcements do not establish wrongdoing. Nevertheless, the increased legal scrutiny adds reputational and potential financial risk and is likely weighing on sentiment. Bragar Eagel & Squire investigation Glancy Prongay Wolke investigation

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.